Harvest Portfolios Group Inc. Has $56.89 Million Holdings in AstraZeneca PLC $AZN

Harvest Portfolios Group Inc. decreased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 814,163 shares of the company’s stock after selling 9,798 shares during the quarter. AstraZeneca accounts for 1.3% of Harvest Portfolios Group Inc.’s investment portfolio, making the stock its 24th biggest holding. Harvest Portfolios Group Inc.’s holdings in AstraZeneca were worth $56,894,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. lifted its holdings in shares of AstraZeneca by 24.0% in the second quarter. Vestmark Advisory Solutions Inc. now owns 84,399 shares of the company’s stock valued at $5,898,000 after purchasing an additional 16,359 shares in the last quarter. Zevin Asset Management LLC raised its position in AstraZeneca by 2.1% in the 2nd quarter. Zevin Asset Management LLC now owns 151,340 shares of the company’s stock valued at $10,576,000 after buying an additional 3,154 shares during the last quarter. Pekin Hardy Strauss Inc. lifted its stake in AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock valued at $255,000 after acquiring an additional 148 shares in the last quarter. Savant Capital LLC boosted its holdings in AstraZeneca by 15.2% during the 2nd quarter. Savant Capital LLC now owns 53,489 shares of the company’s stock worth $3,738,000 after acquiring an additional 7,050 shares during the last quarter. Finally, Modera Wealth Management LLC bought a new stake in shares of AstraZeneca in the 2nd quarter worth $204,000. 20.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Stock Up 3.2%

AZN opened at $83.77 on Friday. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $86.57. The company’s 50-day moving average price is $81.31 and its two-hundred day moving average price is $75.38. The stock has a market cap of $259.80 billion, a price-to-earnings ratio of 31.49, a PEG ratio of 1.52 and a beta of 0.34. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. During the same quarter last year, the business posted $2.08 EPS. AstraZeneca’s quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.